magicmine/iStock via Getty Images
- Krystal Biotech (KRYS) is up ~5% in Friday afternoon trading after reporting additional positive phase 1 data for KB407 for cystic fibrosis.
- The CORAL-1 dose escalation study is examining KB407 at one, two, or four daily administrations via inhalation. The latest data is
